Ondansetron (Zofran) has the potential to prolong repolarization and the labeling has a warning to that effect. In this review an extensive data search found a low risk of arrhythmia. The main concern is with repeated intravenous doses in patients with other risk factors. Via Medpage Today.
No comments:
Post a Comment